KENVUE INC (NYSE:KVUE) reported second-quarter adjusted earnings and revenue that fell short of analyst expectations, with shares indicated lower in pre-market trading as investors weighed a mixed consumer health print against the backdrop of its pending acquisition by Kimberly-Clark.
Earnings versus estimates
Kenvue generated net sales of $3.955 billion in the fiscal second quarter ended June 28, 2026, up 3.0% from $3.839 billion a year earlier but about 2.2% below the $4.045 billion consensus. Adjusted diluted EPS came in at $0.31, up from $0.29 in the prior-year period but roughly 4.8% below the $0.326 analysts had modeled. The shortfall was visible across the top and bottom lines; organic sales grew 1.6%, with volume growth of 0.7% and value realization of 0.9%.
Key second quarter metrics
- Net sales: $3.955 billion, about 2.2% below consensus.
- Adjusted diluted EPS: $0.31, roughly 4.8% below consensus.
- GAAP diluted EPS: $0.24, up from $0.22.
- Organic sales growth: +1.6%, with volume growth of 0.7% and value realization of 0.9%.
- Adjusted gross profit margin: 60.2%, down 70 basis points year over year.
- Adjusted operating income margin: 22.1%, down 60 basis points year over year.
- First-half free cash flow: $1.0 billion, up from $0.8 billion.
Management attributed the margin pressure to inflation, tariffs, and unfavorable transactional foreign exchange, partially offset by supply chain productivity gains and favorable value realization. Higher brand support spending also weighed on the adjusted operating margin.
Segment trends
Growth was positive across all three operating segments, but the pace varied.
- Self Care: Net sales rose 2.2%, with organic growth of 0.6%. A return to organic growth in the U.S. was a key driver, helped by Zyrtec share gains and Pepcid's continued outperformance.
- Skin Health and Beauty: Net sales increased 5.1%, with organic growth of 3.7%. The segment was the strongest, supported by Neutrogena, OGX, and recent innovations.
- Essential Health: Net sales grew 2.3%, with organic growth of 1.1%. Wound care and baby care led, more than offsetting a decline in oral care.
Kenvue also announced FDA approval for Tylenol with Naproxen, described as the first OTC fixed-dose combination of acetaminophen and naproxen sodium. The product is expected to reach major U.S. retailers soon.
Market reaction and outlook
Shares were indicated roughly 2.6% lower in pre-market trading following the report. The pullback comes after the stock gained 2.8% over the previous two weeks and about 2% over the past month, leaving room for a more muted reaction to the earnings miss.
Kenvue did not issue forward-looking guidance and will not host a quarterly conference call because of the pending transaction with Kimberly-Clark. That decision is neutral for the quarter, but it shifts focus to management's execution and the deal timeline. The company continues to expect the transaction to close in the fourth quarter, subject to foreign regulatory approvals and customary conditions.
Risks remain on the margin side, including tariffs, currency volatility, and a dynamic consumer environment. With the acquisition still pending, near-term estimates may carry more uncertainty than usual.
Investors can review additional historical earnings data here, and future revenue and EPS projections can be viewed here.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Kenvue (NYSE:KVUE) Falls After Q2 Earnings Miss as Kimberly-Clark Deal Looms
KENVUE INC (NYSE:KVUE) reported second-quarter adjusted earnings and revenue that fell short of analyst expectations, with shares indicated lower in pre-market trading as investors weighed a mixed consumer health print against the backdrop of its pending acquisition by Kimberly-Clark.
Earnings versus estimates
Kenvue generated net sales of $3.955 billion in the fiscal second quarter ended June 28, 2026, up 3.0% from $3.839 billion a year earlier but about 2.2% below the $4.045 billion consensus. Adjusted diluted EPS came in at $0.31, up from $0.29 in the prior-year period but roughly 4.8% below the $0.326 analysts had modeled. The shortfall was visible across the top and bottom lines; organic sales grew 1.6%, with volume growth of 0.7% and value realization of 0.9%.
Key second quarter metrics
Management attributed the margin pressure to inflation, tariffs, and unfavorable transactional foreign exchange, partially offset by supply chain productivity gains and favorable value realization. Higher brand support spending also weighed on the adjusted operating margin.
Segment trends
Growth was positive across all three operating segments, but the pace varied.
Kenvue also announced FDA approval for Tylenol with Naproxen, described as the first OTC fixed-dose combination of acetaminophen and naproxen sodium. The product is expected to reach major U.S. retailers soon.
Market reaction and outlook
Shares were indicated roughly 2.6% lower in pre-market trading following the report. The pullback comes after the stock gained 2.8% over the previous two weeks and about 2% over the past month, leaving room for a more muted reaction to the earnings miss.
Kenvue did not issue forward-looking guidance and will not host a quarterly conference call because of the pending transaction with Kimberly-Clark. That decision is neutral for the quarter, but it shifts focus to management's execution and the deal timeline. The company continues to expect the transaction to close in the fourth quarter, subject to foreign regulatory approvals and customary conditions.
Risks remain on the margin side, including tariffs, currency volatility, and a dynamic consumer environment. With the acquisition still pending, near-term estimates may carry more uncertainty than usual.
Investors can review additional historical earnings data here, and future revenue and EPS projections can be viewed here.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »